A recent study found that inhibition of FOXO1 alleviates the pathological changes and ovarian dysfunction in PCOS rat models by inhibiting the TLR4/NF-κB/NLRP3 pathway to alleviate inflammation and immune responses (47). Here, NLRP3 is linked to polycystic ovary syndrome.